Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by Law.com, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!

X

Merck dealt blow in Fosamax case

Jury awards plaintiff $285,000

Merck & Co. has had a good run so far as it fights off plaintiffs saying the company’s osteoporosis drug Fosamax caused them health problems—claiming victory in five of the seven bellwether cases to go to trial. But yesterday, a jury in Manhattan dealt Merck a bit of a blow when it awarded a former Fosamax user $285,000 for her injuries.

Rhoda E. Scheinberg took Fosamax for almost six years and claimed she suffered severe jaw problems due to the drug. The jury, saying Merck failed to properly warn users about the potential harmful effects of Fosamax, found in Scheinberg’s favor.

“We disagree with the jury’s verdict,” Chilton Varner, a partner at King & Spalding, told the Wall Street Journal Law Blog. The law firm represented Merck in the case. “Merck provided appropriate warnings, and the plaintiff was at increased risk for dental and jaw problems regardless of whether she was taking Fosamax.”

The jury did, however, find for Merck on a claim regarding the drug’s design.

Former Fosamax users have filed more than 4,000 cases against Merck. Bellwether trials are often used to set parameters for future settlements when high numbers of suits are filed against a company.

Read more litigation stories from the past week on InsideCounsel:

Suit claiming Hebrew National hot dogs are not kosher dismissed

Johnson & Johnson will pay $181 million in fees to Houston law firm

Litigation: Food false advertising class actions on the rise

Securities class action firms earned $653 million in fees in 2012

Editor

Cathleen Flahardy

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.